Diabetes aktuell 2008; 6(5): 201-206
DOI: 10.1055/s-0028-1103107
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Die diabetische Retinopathie und Makulopathie – Häufigste mikrovaskuläre Spätkomplikation des Diabetes mellitus

Diabetic nephropathy and maculopathyClaudia Jochmann1 , Eva Martinetz1 , Peter Wiedemann1
  • 1Klinik und Poliklinik für Augenheilkunde (Direktor: Prof. Dr. med. Peter Wiedemann) am Universitätsklinikum Leipzig
Further Information

Publication History

Publication Date:
05 November 2008 (online)

Weltweit ist bis zum Jahr 2030 mit einer Verdopplung der Prävalenz des Diabetes zu rechnen, dabei sollen junge Erwachsene am stärksten betroffen sein. Die hohe Prävalenz und Inzidenz von Netzhautkomplikationen verlangt verstärkte Bemühungen um die Optimierung der Versorgung. Die diabetische Retinopathie und die Makulopathie sind die häufigsten mikrovaskulären Spätkomplikationen bei Diabetes mellitus. Eine frühe Diagnostik und eine stadiengerechte Therapie kann Erblindungen vermeiden.

Man unterscheidet eine nicht proliferative und eine proliferative diabetische Retinopathie mit und ohne diabetisches Makulaödem. Durch den Hausarzt veranlasste Kontrolluntersuchungen bei einem Facharzt für Augenheilkunde sind erforderlich, um die oft symptomlos verlaufenden, aber schon therapiebedürftigen Stadien zu erkennen.

Vor allem bei der proliferativen diabetischen Retinopathie und dem diabetischen Makulaödem kann durch die Lasertherapie eine Sehverschlechterung aufgehalten werden. Mit der Vitrektomie steht außerdem ein operatives Verfahren zur Verfügung, welches auch bei weit fortgeschrittenen Stadien noch eine funktionelle Besserung bringen kann.

It is estimated, that worldwide the prevalence of diabetes mellitus will double by the year 2030. Mainly affected will be young adults. The high prevalence and incidence of complications of the retina requires stronger efforts in respect of a better care. Diabetic retinopathy and maculopathy are the most common microvascular late complications of diabetes mellitus. Early diagnosis and therapy according to the stage of the disease can prevent blindness.

Diabetic retinopathy is differentiated as proliferative or nonproliferative with or without diabetic macula edema. Check–ups by an ophthalmologist are required to detect early stages which are often not causing any symptoms.

Laser therapy can arrest a deterioration of sight especially in proliferative diabetic retinopathy and diabetic macula edema. Vitrectomy is a surgical procedure which can result in a functional amelioration even in late stages of the disease.

Literatur

  • 1 EURODIAB IDDM Complications Study. . Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.  Diabetologia. 1994;  37 278-285
  • 2 Klein R, Klein BE, Moss SE. et al. . The Wisconsin epidemiologic study of diabetic retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.  Arch Ophthalmol. 1984;  102 520-526
  • 3 Klein R, Klein BE, Moss SE. et al. . The Wisconsin epidemiologic study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.  Arch Ophthalmol. 1984;  102 527-532
  • 4 Trautner C, Icks A, Haastert B, Plum F, Berger M.. Incidence of blindness in relation to diabetes. A population–based study.  Diab Care. 1997;  20
  • 5 Trautner C, Haastert B, Berger M, Willich SN.. Blindheit und Diabetes mellitus. Eine Fall–Kontroll–Studie.  Diab Stoffw. 1999;  8 245-249
  • 6 Keen H, Lee LT, Russell D, Miki E, Bennett PH, Lu M.. The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes.  Diabetologia. 2001;  44
  • 7 UKPDS Group. . Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 837-853
  • 8 Klein R, Klein BE, Moss SE, Cruickshanks KJ.. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. The long–term incidence of macular edema.  Ophthalmology. 1995;  102 7-16
  • 9 Malone JI, Morrison AD, Pavan PR, Cuthbertson DD.. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years duration screened for the diabetic control and complications trial.  Diab Care. 2001;  24 522-526
  • 10 DCCT Research Group. . The effect of intensive treatment of diabetes on the development and progression of long–term complications in insulin–dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.  N Engl J Med. 1993;  329 977-986
  • 11 UKPDS Group. . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.  BMJ. 1998;  317 703-713
  • 12 Janka HU, Warram JH, Rand LI, Krolewski AS.. Risk factors for progression of background retinopathy in long–standing IDDM.  Diabetes. 1989;  38 460-464
  • 13 Klein R, Klein BE, Moss SE. et al. . Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?.  Arch Intern Med. 1989;  149 2427-2432
  • 14 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, UK Prospective Diabetes Study Group.  BMJ. 1998;  317
  • 15 Chew EY, Klein ML, Ferris FL. et al. . Association of elevated serum lipid levels with retinal hard exsudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.  Arch Ophthalmol. 1996;  114 1079-1084
  • 16 Danne T, Kordonouri O, Hovener G, Weber B.. Diabetic angiopathy in children.  Diabet Med. 1997;  14 1012-1025
  • 17 Bertram B, Wolf S, Schulte K. et al. . Retinal blood flow in diabetic children and adolescents.  Graefea Arch Clin Exp Ophthalmol. 1991;  229 336-340
  • 18 Klein BE, Moss SE, Klein R.. Effect of pregnancy on progression of diabetic retinopathy.  Diabetes Care. 1990;  13 34-40
  • 19 Sunnes JS.. The pregnant woman's eye.  Surv Ophthalmol. 1988;  32 219-238
  • 20 Horvat M, Maclean H, Goldberg L, Crock GW.. Diabetic retinopathy in pregnancy: a 12–year prospective survey.  Br J Ophthalmol. 1980;  64 398-403
  • 21 Muhlhauser I, Bender R, Bott U, Jorgens V. et al. . Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes.  Diabet Med. 1996;  13 536-543
  • 22 Muhlhauser I, Sawicki P, Berger M.. Cigarette–smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin–dependent) diabetes.  Diabetologia. 1986;  29 500-502
  • 23 Klein BE, Klein R, McBride PE, Cruickshanks KJ. et al. . Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy.  Arch Intern Med. 2004;  164 1917-1924
  • 24 Klein R, Klein BE, Moss SE, Cruickshanks KJ.. Association of ocular disease and mortality in a diabetic population.  Arch Ophthalmol. 1999;  117 1487-1495
  • 25 Klein R, Klein BE, Moss SE, Cruickshanks KJ.. Association of ocular disease and mortality in a diabetes population.  Arch Ophthalmol. 1999;  117 1487-1495
  • 26 Fuller JH, Stevens LK, Wang SL.. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of vascular Disease in Diabetes.  Diabetologia. 2001;  44
  • 27 Bertram B.. Diabetikerbetreuung in deutschen Augenarztpraxen. Augenarzt 1998: 289-291
  • 28 Hauner H, von Ferber L, Köster I.. Ambulante Versorgung von Diabetikern. Eine Analyse von Krankenkassendaten der AOK Dortmund.  Dtsch Med Wschr. 1994;  119 129-134
  • 29 Javittt JC, Canner JK, Frank RG, Steinwachs DM, Sommer A.. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model.  Ophthalmology. 1990;  97 483-494
  • 30 Javitt JC, Aiello LP, Chiang Y, Ferris FL, Canner JK, Greenfield S.. Preventive eye care in people with diabetes is cost–saving to the federal government. Implications for health–care reform.  Diabetes care. 1994;  17 909-917
  • 31 CDC. . The cost–effectiveness of screening for type 2 diabetes. CDC Diabetes Cost–Effectiveness Study Group. Centers for Diesease Control and Prevention.  JAMA. 1998;  280 1757-1763
  • 32 Early Treatment Diabetic Retinopathy Study (ETDRS) Group. . Results and summary.  Ophthalmology. 1991;  5 739-840
  • 33 Global Diabetic Retinopathy Project Group. . Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.  Ophthalmology. 2003;  110 1677-1682
  • 34 Lee CM, Olk RJ.. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long–term visual results.  Ophthalmol. 1991;  998 1594-1602
  • 35 Diabetic Retinopathy Vitrectomy Study Research Group. . Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four–year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.  Arch Ophthalmol. 1990;  108 958-964
  • 36 Otani T, Kishi.. A controlled study of vitrectomy for diabetic macular edema.  Am J Ophthalmol. 2002;  134 214-219
  • 37 Recchia FM, Ruby AJ, Carvalho CA. Recchia. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema.  Am J Ophthalmol. 2005;  139 447-454

Korrespondenz

Dr. med. Claudia Jochmann
Eva Martinetz
Prof. Dr. med. Peter Wiedemann

Klinik und Poliklinik für Augenheilkunde Universitätsklinikum Leipzig AöR

Liebigstraße 10 – 14

04103 Leipzig

Email: Claudia.Jochmann@medizin.uni-leipzig.de

    >